详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

PTPRZ1 dephosphorylates and stabilizes RNF26 to reduce the efficacy of TKIs and PD-1 blockade in ccRCC

0| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Urology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China [2]Department of Urology, The Second Xiangya Hospital,Central South University, Changsha, Hunan 410011, China [3]Uro-Oncology Institute of Central South University, Changsha, Hunan 410011, China [4]Hunan Engineering ResearchCenter of Smart and Precise Medicine, Changsha, Hunan 410011, China [5]Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha,Hunan, China [6]Robotic Minimally Invasive Surgery Center, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China,Chengdu 610072, China [7]Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan Province, China [8]State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, Henan Province, China [9]Henan Engineering Research Center ofPrecision Therapy of Gastrointestinal Cancer, Zhengzhou, Henan Province, China [10]Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, Zhengzhou,Henan Province, China

出处：

DOI：

ISSN：

摘要：

Clear cell renal cell carcinoma (ccRCC), the most common subtype of renal cell carcinoma, often exhibits resistance to tyrosine kinase inhibitors (TKIs) when used as monotherapy. However, the integration of PD-1 blockade with TKIs has significantly improved patient survival, making it a leading therapeutic strategy for ccRCC. Despite these advancements, the efficacy of this combined therapy remains suboptimal, necessitating a deeper understanding of the underlying regulatory mechanisms. Through comprehensive analyses, including mass spectrometry, RNA sequencing, lipidomic profiling, immunohistochemical staining, and ex vivo experiments, we explored the interaction between PTPRZ1 and RNF26 and its impact on ccRCC cell behavior. Our results revealed a unique interaction where PTPRZ1 stabilized RNF26 protein expression by dephosphorylating it at the Y432 site. The modulation of RNF26 levels by PTPRZ1 was found to be mediated through the proteasome pathway. Additionally, PTPRZ1, via its interaction with RNF26, activated the TNF/NF-κB signaling pathway, thereby promoting cell proliferation, angiogenesis, and lipid metabolism in ccRCC cells. Importantly, inhibiting PTPRZ1 enhanced the sensitivity of ccRCC to TKIs and PD-1 blockade, an effect that was attenuated when RNF26 was simultaneously knocked down. These findings highlight the critical role of the PTPRZ1-RNF26 axis in ccRCC and suggest that combining PTPRZ1 inhibitors with current TKIs and PD-1 blockade therapies could significantly improve treatment outcomes for ccRCC patients.© 2024. The Author(s), under exclusive licence to Springer Nature Limited.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区生化与分子生物学 1 区遗传学 2 区细胞生物学 2 区肿瘤学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q1 CELL BIOLOGY Q1 GENETICS & HEREDITY Q1 ONCOLOGY

影响因子： 6.9 最新[2023版] 7.5 最新五年平均 6.9 出版当年[2023版] 0 出版当年五年平均 6.9 出版前一年[2023版]

第一作者：

第一作者机构： [1]Department of Urology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

共同第一作者：

通讯作者：

通讯机构： [2]Department of Urology, The Second Xiangya Hospital,Central South University, Changsha, Hunan 410011, China [3]Uro-Oncology Institute of Central South University, Changsha, Hunan 410011, China [4]Hunan Engineering ResearchCenter of Smart and Precise Medicine, Changsha, Hunan 410011, China [7]Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan Province, China [8]State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, Henan Province, China [9]Henan Engineering Research Center ofPrecision Therapy of Gastrointestinal Cancer, Zhengzhou, Henan Province, China [10]Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, Zhengzhou,Henan Province, China

推荐引用方式(GB/T 7714)：

APA：

MLA：